Teva Pharmaceutical Archives

Home / Posts tagged Teva Pharmaceutical

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments across Europe These approvals mark another significant milestone in Teva’s strong biosimilars portfolio, in line with Teva’s Pivot to Growth Strategy [...]

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

TEL AVIV, Israel, Nov. 21, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, and other members of executive management will present at three upcoming investor conferences in December as follows: 8th Annual Evercore Healthcare Conference Wednesday, December 3, 2025, at 8:20 A.M. [...]

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024 Partnership brings together both companies’ expertise in biosimilars TEL AVIV, Israel, Oct. 20, 2025 (Korea Bizwire) – Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries [...]

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.1 UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults.1 This approval [...]

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

TEL AVIV, Israel, June 25, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on [...]

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

TEL AVIV, Israel, May 22, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it is increasing the maximum tender amount of its tender offer previously announced on May 19, 2025 from $2.0 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) to approximately $2.25 [...]

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

TEL AVIV, Israel, May 20, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “Notes”). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects [...]

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states SANTA BARBARA, Calif. and PARSIPPANY, N.J. , Feb. 27, 2025 (Korea Bizwire) – Direct Relief, Teva Pharmaceuticals, and the National Association of Free and Charitable Clinics [...]

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement Findings to form the basis [...]

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO® - exceeding $1.6 billion in revenues, surpassing 2024 outlook; AJOVY® - global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023; UZEDY® revenues of $117 million in 2024 surpassing $100M outlook; Generics business [...]